Lucid Diagnostics Inc (NASDAQ: LUCD)’s stock price has gone rise by 20.02 in comparison to its previous close of 0.75, however, the company has experienced a 24.62% increase in its stock price over the last five trading days. InvestorPlace reported 2024-04-19 that Let’s just get something straight off the bat – penny stocks to rebound are risky. They’re incredibly treacherous in terms of both short-term downside and longer-term damage to your portfolio.
Is It Worth Investing in Lucid Diagnostics Inc (NASDAQ: LUCD) Right Now?
The stock has a 36-month beta value of 1.61. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for LUCD is 14.29M, and at present, short sellers hold a 2.53% of that float. On May 01, 2024, the average trading volume of LUCD was 177.14K shares.
LUCD’s Market Performance
LUCD’s stock has seen a 24.62% increase for the week, with a 0.33% rise in the past month and a -35.64% fall in the past quarter. The volatility ratio for the week is 11.83%, and the volatility levels for the past 30 days are at 8.14% for Lucid Diagnostics Inc The simple moving average for the past 20 days is 10.11% for LUCD’s stock, with a -30.62% simple moving average for the past 200 days.
Analysts’ Opinion of LUCD
Many brokerage firms have already submitted their reports for LUCD stocks, with Ascendiant Capital Markets repeating the rating for LUCD by listing it as a “Buy.” The predicted price for LUCD in the upcoming period, according to Ascendiant Capital Markets is $16 based on the research report published on December 27, 2021 of the previous year 2021.
Needham, on the other hand, stated in their research note that they expect to see LUCD reach a price target of $17. The rating they have provided for LUCD stocks is “Buy” according to the report published on November 08th, 2021.
Cantor Fitzgerald gave a rating of “Overweight” to LUCD, setting the target price at $21 in the report published on November 08th of the previous year.
LUCD Trading at -12.60% from the 50-Day Moving Average
After a stumble in the market that brought LUCD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -51.30% of loss for the given period.
Volatility was left at 8.14%, however, over the last 30 days, the volatility rate increased by 11.83%, as shares surge +1.35% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -33.75% lower at present.
During the last 5 trading sessions, LUCD rose by +24.62%, which changed the moving average for the period of 200-days by -32.26% in comparison to the 20-day moving average, which settled at $0.8189. In addition, Lucid Diagnostics Inc saw -36.10% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at LUCD starting from Lapidus Stanley, who sale 29,747 shares at the price of $1.45 back on Sep 26 ’23. After this action, Lapidus Stanley now owns 101,592 shares of Lucid Diagnostics Inc, valued at $43,173 using the latest closing price.
Lapidus Stanley, the Director of Lucid Diagnostics Inc, sale 200 shares at $1.43 during a trade that took place back on Sep 25 ’23, which means that Lapidus Stanley is holding 131,339 shares at $286 based on the most recent closing price.
Stock Fundamentals for LUCD
Current profitability levels for the company are sitting at:
- -19.97 for the present operating margin
- -1.72 for the gross margin
The net margin for Lucid Diagnostics Inc stands at -830.18. The total capital return value is set at 22.96. Equity return is now at value -507.97, with -176.20 for asset returns.
Based on Lucid Diagnostics Inc (LUCD), the company’s capital structure generated 1.18 points at debt to capital in total, while cash flow to debt ratio is standing at -2.15. The debt to equity ratio resting at -6.6. The interest coverage ratio of the stock is -116.54.
Currently, EBITDA for the company is -45.98 million with net debt to EBITDA at 0.07. When we switch over and look at the enterprise to sales, we see a ratio of 16.4. The receivables turnover for the company is 53.96for trailing twelve months and the total asset turnover is 0.09. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.75.
Conclusion
To sum up, Lucid Diagnostics Inc (LUCD) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
